Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPR1 | P16066 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pivalate SCHEMBL27573360 | 0.84 | CA12 (0.38) | AHRCA9CA12CA2CYP2B6 | |
| SCHEMBL29274342 | 0.84 | STS (0.49) | AHRCA9CA12CA2CYP2B6 | |
| SCHEMBL2113039 | 0.81 | LMNA (0.47) | AHRCA9CA12CA2MAPT | |
| SCHEMBL11872738 | 0.79 | MAPT (0.44) | AHRCA9CA12CA2MAPT | |
| SCHEMBL4550984 | 0.76 | CYP2B6 (0.46) | CA9CYP2B6STSCYP1A2CYP1B1 | |
| SCHEMBL2007996 | 0.76 | CYP2B6 (0.42) | CA9CYP2B6STSCYP1A2CYP1B1 | |
| SCHEMBL3199320 | 0.76 | AHR (0.45) | AHRCA9CYP2B6MAPTLMNA | |
| SCHEMBL1192912 | 0.76 | CYP3A4 (0.45) | CA9CA12CA2CYP2B6MAPT | |
| SCHEMBL18617980 | 0.76 | CYP2B6 (0.42) | CA9CYP2B6STSCYP1A2CYP1B1 | |
| SCHEMBL5390733 | 0.76 | CYP2B6 (0.42) | CA9CYP2B6STSCYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276962-A1 | CONTRACEPTIVE COMPOUNDS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2025-09-04 | — | — | US | disclosed |
| US-12281105-B2 | Contraceptive compounds and methods | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2025-04-22 | — | — | US | disclosed |
| CN-117881674-A | Contraceptive compounds and methods | 明尼苏达大学董事会 | 2024-04-12 | — | — | CN | disclosed |
| US-20240109872-A1 | CONTRACEPTIVE COMPOUNDS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-04-04 | — | — | US | disclosed |
| EP-4334309-A1 | CONTRACEPTIVE COMPOUNDS AND METHODS | Regents of the University of Minnesota (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11780828-B2 | Contraceptive compounds and methods | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220388993-A1 | CONTRACEPTIVE COMPOUNDS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-12-08 | — | — | US | disclosed |
| WO-2022235693-A1 | CONTRACEPTIVE COMPOUNDS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-11-10 | — | — | WO | disclosed |
| US-8569312-B2 | Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569312-B2 | Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20060229318-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | US | disclosed |
| EP-1710240-A1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | Les Laboratoires Servier (FR) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005042509-A1 | 7-`(7-ALKOXY)-CHROM-3-EN-6-YL!-HEPTATRIENOIC ACID AND 7-`(3ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL!-HEPTATRIENOIC ACID DERIVATIVES MODULATORS | ALLERGAN, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096380-A1 | 7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | ALLERGAN, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6887896-B1 | 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity | ALLERGAN, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-6590048-B1 | Catalysts comprising group VIII compounds used for cyclization of crown ethers, antibiotics, veterinary medicines or perfumes | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2003-07-08 | — | — | US | disclosed |
| EP-1037897-B1 | HIGHLY ACTIVE CATIONIC RUTHENIUM AND OSMIUM COMPLEXES FOR OLEFIN METATHESIS REACTIONS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2002-06-12 | — | — | EP | disclosed |
| US-6201131-B1 | REACTING A 2-(ARYLSUFONYL) ETHANOL DERIVATIVE WITH AN ACID ANHYDRIDE IN PRESENCE OF A BASE, FURTHER REACTING THIS WITH AN AROMATIC HALIDE IN THE PRESENCE OF A PALLADIUM CATALYST; USEFUL AS INTERMEDIATES TO DRUGS, AGROCHEMICALS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-03-13 | — | — | US | disclosed |
| EP-1037897-A1 | HIGHLY ACTIVE CATIONIC RUTHENIUM AND OSMIUM COMPLEXES FOR OLEFIN METATHESIS REACTIONS | Studiengesellschaft Kohle mbH (DE) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999028330-A1 | HIGHLY ACTIVE CATIONIC RUTHENIUM AND OSMIUM COMPLEXES FOR OLEFIN METATHESIS REACTIONS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276962-A1 | CONTRACEPTIVE COMPOUNDS AND METHODS | CYP19A1, GNRHR, NR5A1 | AHR 1980/4885CA9 1119/4885CA12 1060/4885 |
| US-11780828-B2 | Contraceptive compounds and methods | CYP19A1, GNRHR, NR5A1 | AHR 1980/4885CA9 1119/4885CA12 1060/4885 |
| US-20050096380-A1 | 7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | TPO, THRA, FABP6 | AHR 434/4885CA9 1342/4885CA12 2594/4885 |
| US-20240109872-A1 | CONTRACEPTIVE COMPOUNDS AND METHODS | CYP19A1, GNRHR, NR5A1 | AHR 1980/4885CA9 1119/4885CA12 1060/4885 |
| US-20220388993-A1 | CONTRACEPTIVE COMPOUNDS AND METHODS | CYP19A1, GNRHR, NR5A1 | AHR 1980/4885CA9 1119/4885CA12 1060/4885 |
| US-20060229318-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | AHR 99/4885CA9 3957/4885CA12 4035/4885 |
| US-12281105-B2 | Contraceptive compounds and methods | CYP19A1, GNRHR, NR5A1 | AHR 1980/4885CA9 1119/4885CA12 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.